AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 51 min read$VSTM

Paterson Dan sold $8K of VSTM

Paterson Dan (President and CEO) sold 1,302 shares of Verastem, Inc. (VSTM) at $5.81 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Paterson Dan
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VSTM
Neutral
high confidence
Mentioned
$VSTM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMNeutralLow
01

Why it matters

The newest fact is the CEO’s Aug 3 open-market sale amount and price, filed on Aug 5. This can influence short-term sentiment but does not introduce new business or financial guidance.

02

Market read

Traders may note insider selling, but the 10b5-1 structure reduces interpretive weight versus an unplanned sale.

03

What to watch

The article provides only the sale details, not total insider ownership changes over time or any concurrent company-specific catalysts.

Relevance 2/10Novelty 3/10Timing: Filed Aug 5, covering an Aug 3 sale.

Background

The article is a SEC Form 4 insider transaction disclosure for Verastem, Inc. (VSTM).

Company-level read

Ticker impact

$VSTMNeutralHigh confidence
Context

Verastem CEO Paterson Dan filed a Form 4 open-market sale of 1,302 shares at $5.81 on Aug 3 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine 10b5-1 planned sale by the CEO, with no accompanying guidance, operational change, or transaction terms indicating new corporate risk.

Market effects

Sector

Minimal. Insider 10b5-1 sales are common and do not typically signal sector-wide changes.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • issuer
    Verastem, Inc.

    Company whose CEO insider sale is disclosed on Form 4.

  • insider
    Paterson Dan

    President and CEO who sold 1,302 shares at $5.81 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VSTM insider trading history →

Related articles

OCT 5
$VSTMMedAI 8/10

Verastem shares get Buy rating reiterated by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating on Verastem (VSTM) with a $18.00 price target, citing positive clinical data for avutometinib plus defactinib in ovarian cancer. The stock trades at $7.70, with a Strong Buy consensus. Verastem reported a narrower-than-expected Q2 2026 loss and revenue exceeding forecasts, driven by product sales and a license payment. Cantor Fitzgerald also reiterated an Overweight rating.

investing.com2 min
OCT 2
$VSTMHighAI 9/10

Verastem presents new data on ovarian cancer drug combination

Verastem Oncology presented data from its Phase 2 RAMP 201 trial, showing positive results for its drug combination in treating recurrent low-grade serous ovarian cancer. The combination achieved objective response rates of 22% and 18% in specific patient groups, with median progression-free survival of 13 months. The FDA approved the combination in May 2025, pending confirmatory trial results. The data was presented at the International Gynecologic Cancer Society Annual Global Meeting.

investing.com2 min
AUG 20
$VSTMHighAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 revenue of $40.1M, including $25.1M from product sales and a $15M milestone. Net loss was $30.6M, down from $41.3M YoY. Cash position is $136.4M, with a pro forma balance of $201.4M. The company expects cash runway into 2H 2027 and LGSOC business self-sustainability by year-end. Clinical trials for VS-7375 are progressing, with Phase III plans for 2027.

aol.com3 min
AUG 14
$VSTMMedAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 net product revenue of $25.1M from the AVMAPKI FAKZYNJA CO-PACK launch and total revenue of $40.1M, including a $15M Secura Bio milestone. Non-GAAP adjusted net loss was $30.6M ($0.31/share). Cash and investments were $136.4M; pro forma cash $201.4M. VS-7375 Phase II trials advanced.

fool.com14 min
AUG 7
$VSTMMedAI 8/10

Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

sci-tech-today.com6 min